Healthcare

Invex Therapeutics (ASX:IXC) traded at AUD 0.10 on 22 April 2026, unchanged on the session, as the market absorbed a quarterly update centred on research progress rather than immediate commercial milestones. For development-stage biopharmaceutical companies, flat price action often reflects a market awaiting more …

Noxopharm Limited (ASX:NOX) shares increased by 1.45% to AUD 0.070 during the morning session on 24 April 2026, following the release of its March 2026 Quarterly Activities Report and Appendix 4C. Despite today’s upward movement, the stock remains 12.50% lower over the past year, …

Mach7 Technologies Ltd (ASX:M7T) saw its share price decline 3.51% to AUD 0.28 during the morning session on 24 April 2026, following the release of its Q3 FY26 business update and quarterly cashflow report. The stock remains down 16.67% over the past year, with …

This note presents the factual context of the 23 April 2026 share price move, provides a concise overview of Lumos Diagnostics Holdings Limited's business, outlines the likely and plausible drivers of the move (in the absence of a specific company-issued announcement identifiable on the …

Racura Oncology Ltd is an ASX-listed clinical-stage oncology biotech company engaged in radiopharmaceutical oncology company developing targeted alpha therapies for prostate and other solid-tumour cancers, with lead programme advancing through late-stage clinical trials and positioning toward potential regulatory submission. The company's operating profile positions …

Ramsay is in an unusual transitional phase. In February 2026, the company concluded its strategic review of Ramsay Santé, its 52.8%-owned European hospital subsidiary, and announced that the preferred outcome was an in-specie distribution of its Ramsay Santé shareholding directly to Ramsay shareholders. The …

This note presents the factual context of the 23 April 2026 share price move, provides a concise overview of Tetratherix Limited's business, outlines the likely and plausible drivers of the move (in the absence of any specific company-issued announcement identifiable on the day), discusses …